BTIG has adjusted its outlook on ProKidney Corp. (NASDAQ: PROK), reducing the price target to $5 from the previous $6, while reiterating its Buy rating on the company's shares. The adjustment follows ProKidney's second-quarter earnings report for 2024, which included updates on the company's clinical studies and manufacturing operations.
ProKidney has recently resumed manufacturing and its Phase 3 clinical studies, PROACT 1 and 2, after receiving a QP Declaration of Equivalence. The company's Phase 2 REGN-007 open-label study, which involved patients with stage 3/4 diabetic chronic kidney disease (CKD), showed promising results in June, with kidney function stabilization over 18 months. These findings are seen as a positive indicator for the ongoing Phase 3 studies.
The company made strategic changes to its rilparencel development program following the Phase 2 RMCL-002 study results in November. Management decided to focus on patients with more advanced stage 3/4 CKD, revising the enrollment criteria for the Phase 3 PROACT 1 study. The new range for estimated glomerular filtration rate (EGFR) is now set between ≥20 and ≤35 ml/min/1.73m^2, narrowed from the previous range of ≥20 to ≤50 ml/min/1.73m^2.
BTIG views the change in enrollment criteria positively, believing it will demonstrate a more significant improvement in patients with severe CKD. This focus on a population with higher unmet medical needs could also enhance the drug's value proposition and its pharmacoeconomic profile, potentially influencing payor reimbursement decisions.
ProKidney Corp. reported positive interim results from its Phase 2 REGEN-007 trial, demonstrating stabilization of kidney function in patients with chronic kidney disease caused by diabetes. The company also launched a $125 million share offering to fund various corporate activities including clinical trials and research and development. Analyst firms have responded to these developments, with BofA Securities maintaining a Neutral stance on ProKidney stock and a steady price target of $4.00, while BTIG assigned a Buy rating and a $6.00 price target.
Jefferies, however, reduced its price target to $6.00 but retained a Buy rating. These ratings reflect the analysts' cautious optimism about ProKidney's future prospects, particularly the potential of its REACT treatment for chronic kidney disease.
BofA Securities also noted the resumption of enrollment for ProKidney's pivotal trials, Proact-1 and Proact-2, following the receipt of a Quality Person Declaration of Equivalence to European Union Good Manufacturing Practices.
InvestingPro Insights
As ProKidney Corp. (NASDAQ: PROK) navigates the challenges of its clinical studies and strategic shifts, recent data from InvestingPro provides a snapshot of the company's financial health and market performance. With a market capitalization of $602.52 million, ProKidney holds a notable position in its sector. Notably, the company has experienced a significant return over the last week, with a 13.04% price total return, reflecting a positive reaction in the market to recent developments.
InvestingPro Tips highlight that ProKidney is not profitable over the last twelve months, which aligns with analysts' expectations that the company will not be profitable this year. Additionally, the company's net income is expected to drop this year, emphasizing the importance of its clinical trials' outcomes. With the company's liquid assets exceeding short-term obligations, ProKidney maintains some financial flexibility, which could be crucial as it continues to burn through cash quickly.
For investors looking for more in-depth analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/PROK, which could provide further guidance on the company's financial trajectory and investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.